Phathom Pharmaceuticals Inc (NASDAQ:PHAT) reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episodic heartburn in non-erosive gastroesophageal reflux disease (NERD).
- All three vonoprazan dose levels met the primary endpoint and were statistically significant compared to placebo in the study.
- Within three hours, vonoprazan 10 mg, 20 mg, and 40 mg achieved complete and sustained relief in 56.0%, 60.6%, and 70.0% of evaluable heartburn episodes, respectively, compared to 27.3% on placebo.
- Related: Phathom's Vonoprazan Non-Inferior To Proton Pump Inhibitor For Esophagitis Inflammation.
- The PHALCON-NERD trial also included an open-label daily dosing run-in phase where all participants enrolled received vonoprazan 20 mg once daily (QD) for four weeks.
- Over this period, the mean percentage of 24-hour heartburn-free days observed was 65.4% (median 76.0%).
- Phathom has initiated NERD-301 Phase 3 for vonoprazan 10 mg and 20 mg as daily dosing (QD) therapy for NERD.
- The Company expects to report topline results from NERD-301 in 2023.
- Price Action: PHAT shares traded 3.50% higher at $17.91 on the last check Thursday.
